Eliana Clark - 01 Mar 2024 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Signature
James Basta, attorney-in-fact
Issuer symbol
NTLA
Transactions as of
01 Mar 2024
Net transactions value
-$19,959
Form type
4
Filing time
05 Mar 2024, 16:10:16 UTC
Previous filing
05 Jan 2024
Next filing
03 Jul 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NTLA Common Stock Award $0 +31,230 +76% $0.000000 72,075 01 Mar 2024 Direct F1
transaction NTLA Common Stock Sale $19,959 -605 -0.84% $32.99 71,470 04 Mar 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NTLA Stock Option (right to buy) Award $0 +45,072 $0.000000 45,072 01 Mar 2024 Common Stock 45,072 $32.66 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
F2 Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on March 1, 2024, and does not represent a volitional trade by the Reporting Person.
F3 This option was granted on March 1, 2024 with respect to shares of Common Stock, with 33% vesting on January 1, 2025 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.